NGD 971
Alternative Names: CP457920; NGD 97-1Latest Information Update: 27 Jan 2011
Price :
$50 *
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; Pfizer
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action GABA A receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 24 Jan 2011 Discontinued - Phase-II for Vascular dementia in USA (unspecified route)
- 10 May 2004 Discontinued - Phase-II for Alzheimer's disease in USA (unspecified route)
- 05 May 2004 Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the Alzheimer's disease therapeutic trials section